Heart Failure

A study of patients recommended for statin therapy under ACC/AHA guidelines, but not taking any, found that 59.2% reported never being offered a statin.

A new cohort assessment shows white and African American men both have a lifetime hypertension risk of more than 80%.

Investigators observed a 22% and 20% increased risk of heart failure during the 2 most severe influenza seasons.

How the PIONEER-HF and PARADIGM-HF trials have focused on varied, but realistic heart failure patients.

A year-long outpatient care study showed that patients with type 2 diabetes and comorbid cardiovascular disease are 5 times as likely to visit a cardiologist.

A new long-term data analysis reports that about 50% of patients adhere to the critcal therapy after just 1 year, and the rate continues to drop after that.

The breakthrough device is indicated to improve 6-minute walk distance for certain patients with chronic heart failure.

With cardiovascular drug classes inhibitors owning discussion, how will recent or upcoming guideline updates address their use alongside lifestyle management?

Progress in invasive measures for cardiovascular conditions has allowed clinicians the ability to venture into new ground.

An extension of the study showed sacubitril/valsartan's benefit as an initial hospitalized heart failure therapy.

How alirocumab fared for patients with polyvascular disease in a subset of the major clinical trial.

Heart disease is the greatest cause of death in women, and Wood believes female patients would better from a multidisciplinary approach.

Among participants of the EMPA-REG OUTCOME trial who experienced heart failure, empagliflozin was associated with lower rates of short-term re-hospitalization and death.

A 5000-plus patient study found that about 80% of young women have never been administered a lipid test.

The rate of heart attacks among patients under 40 years old has been increasing by 2% annually for the past decade.

Now that SGLT-2 inhibitors have reached the market, how will clinicians compare their benefits in patients?

How advancing stent therapy options have come to bridge the gap between improving and elongating a patient's life.

How the effective cardiovascular drug class have reach a state of impending head-to-head trials.

A system which rewards hospitals based on their patient readmission rates may not be considering other factors of care.

A prospective study found that daily dapagliflozin significantly improved mitral flow, left ventricular mass index, and left atrial volume index after 6 months of treatment.

No head-to-head trials exist for the inhibitors, but current data shows consistency across the board for each drug.

Patients who received a flu shot had a lower rate of myocardial infarction, according to new research.